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Abstract
The prognostic importance of transcription factors promoting epithelial–mesenchymal transition (EMT) and
angiogenesis has not been well explored in prostate cancer patients with long follow-up, nor the interplay
between these factors. The objective of this study was to assess the individual protein expression and co-
expression of Twist, Slug (Snai2), Snail (Snai1), and hypoxia-inducible factor-1 alpha (Hif-1α) in prostate cancer
in relation to EMT, angiogenesis, hypoxia, tumour features, disease recurrence, and patient survival. Immunohis-
tochemical staining was performed on tissue microarray sections from 338 radical prostatectomies with long
follow-up. In addition, 41 cases of prostatic hyperplasia, 33 non-skeletal metastases, 13 skeletal metastases, and
33 castration-resistant prostate carcinomas were included. Our findings were validated in external gene expres-
sion data sets. Twist was overexpressed in primary prostate cancer and markedly reduced in distant metastases
(p < 0.0005). Strong expression of Twist and Slug was associated with Hif-1α in localised prostate cancer
(p ≤ 0.001), and strong Twist was associated with Hif-1α in castration-resistant carcinomas (p = 0.044). Twist,
Slug, and increased Snail at the tumour stromal border were associated with vascular factors (p ≤ 0.045). Each
of the three EMT-regulating transcription factors were associated with aggressive tumour features and shorter
time to recurrence and cancer-specific death. Notably, the co-expression of factors demonstrated an enhanced
influence on outcome. In the subgroup of E-cadherinlow carcinomas, strong Slug was associated with shorter time
to all end points and was an independent predictor of time to multiple end points, including cancer-specific
death (hazard ratio 3.0, p = 0.041). To conclude, we demonstrate an important relation between EMT, hypoxia,
and angiogenesis and a strong link between the investigated EMT regulators and aggressive tumour features and
poor patient outcome in prostate cancer. Despite the retrospective nature of this long-term study, our findings
could have a significant impact on the future treatment of prostate cancer, where tailored therapies might be
directed simultaneously against epithelial–mesenchymal phenotypes, angiogenesis, and tumour hypoxia.
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Introduction
Epithelial tumour cells can convert to a mesenchymal-
like phenotype, thereby making invasion and metastasis
possible [1,2]. This trans-differentiation programme,
epithelial–mesenchymal transition (EMT), is seen not
only in aggressive carcinomas but also during embry-
onic development, fibrosis, and wound healing [1–3].
Tumour EMT is induced by signalling pathways,
including transforming growth factor β, Wnt, and Notch
[1]. The stromal cells in the tumour microenvironment
can secrete cytokines, chemokines, and growth factors
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and thereby induce EMT [4], and hypoxia is known
to induce EMT by upregulation of factors such as
hypoxia-inducible factor-1 alpha (Hif-1α) [1,5].
EMT is driven and coordinated by master regula-
tors, including Twist, Slug (Snai2), and Snail (Snai1),
which are able to activate mesenchymal genes and
repress epithelial genes [6]. These pathways are
dependent on the context, as well as the tissue, and
the EMT regulators have been shown to regulate each
other in complicated, hierarchical, and interdependent
manners [7]. Hence, in addition to examining the
expression of individual EMT regulators in carcino-
mas, the impact of their co-expression is of great
interest [5,8–10].
Twist, Slug, and Snail differ both structurally and
functionally [7]. Although Slug and Snail share a simi-
lar structural organisation, it appears that they still play
different roles in EMT [11] and are expressed differ-
ently [12]. Twist induces expression of mesenchymal
markers such as N-cadherin [13–15], fibronectin, and
vimentin [14,15] and promotes proliferation, facilitates
intravasation [14], inhibits apoptosis, and reduces sen-
sitivity to chemotherapy [14,16,17]. Slug and Snail act
as repressors on the E-cadherin (CDH1) promoter
[2,18]. They also affect proliferation and have pro-
survival activity [18]. Increased Snail expression has
been found especially at the invasive front in carcino-
mas [19,20].
In addition, a relationship between EMT and angio-
genesis has been suggested. Twist is shown to have a
pro-angiogenic effect through increased vascular endo-
thelial growth factor (VEGF) in studies on pancreatic
cancer [21] and breast cancer [14,22,23], and Slug and
Snail have also been linked to angiogenesis via VEGF
[24]. However, little is reported on this possible con-
nection between EMT, hypoxia, and angiogenesis on
clinical tumour specimens from prostate cancer
patients.
Twist, Slug, and Snail are associated with aggres-
sive features and disease progression in several cancers
[8,25–30] but are studied to a lesser extent in prostate
cancer [31–39], where studies presenting end points
beyond biochemical recurrence are still unavailable.
Here, we evaluated the expression of Twist, Slug, and
Snail in different prostatic tissues. Hif-1α was re-
evaluated, after being assessed in a previous study
[40], in our current larger series with extended follow-
up. We focused particularly on co-expression of the
biomarkers, as well as on potential novel links
between EMT, hypoxia, and angiogenesis. Further-
more, relations to clinicopathological features and
patient survival were examined as factors that control
epithelial–mesenchymal states are attractive targets for
cancer therapy. Our study supports a central role for
these EMT regulators, with findings that could affect
the future management of prostate cancer.
Materials and methods
Patients and tissues
As previously described [41], series 1–5 include the
following: series 1, radical prostatectomy specimens
from patients (n = 338) with clinically localised pros-
tate cancer, treated from 1986 to 2007 at Haukeland
University Hospital, Bergen, Norway; series 2, pros-
tate tissues (n = 41) of benign prostatic hyperplasia
(BPH); series 3, non-skeletal metastases (27 lymph
node metastases and 6 distant soft tissue metastases
[testis, rectum, bronchial mucosa, orbita, skeletal
muscle, and subcutaneous tissue]); series 4, skeletal
metastases (n = 13); and series 5; prostate cancer tis-
sues from castration-resistant prostate cancer (CRPC)
patients (n = 33) treated by transurethral resection for
palliation purposes from 1990 to 2005. Five lymph
node metastases in series 3 match with patients in
series 1 as pelvic lymphadenectomy was performed
along with radical prostatectomy on these patients.
The tumours are principally acinar adenocarcinomas
as previously reported [41]. This study was approved
by the Western Regional Committee for Medical and
Health Research Ethics, REC West (REK
2015/2178).
Clinicopathological variables
For series 1, the following variables were retrieved
from the clinical patient files: age at diagnosis, date of
primary diagnosis, date of prostatectomy, preoperative
and postoperative serum prostate-specific antigen (s-
PSA), and clinical TNM stage [42]. From the pathol-
ogy reports, Gleason grading, extra-prostatic exten-
sion, seminal vesicle invasion, involvement of surgical
margins, pelvic lymph node status at prostatectomy,
and largest tumour dimension were recorded (see sup-
plementary material, Table S1). s-PSA was introduced
in the early 1990s in Norway. Consequently, the
patients in the first part of series 1 more often had pal-
pable tumours, clinical stage T2, with locally advanced
pathological stages compared with prostate-specific
antigen (PSA)-detected tumours, which were largely
clinical stage T1C, in the second part. Because of the
long study period, series 1 was re-examined and
Gleason graded according to the recommendations
from the International Society of Urological Pathology
254 A Børretzen et al
© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society
of Great Britain and Ireland & John Wiley & Sons, Ltd.
J Pathol Clin Res 2021; 7: 253–270
(ISUP) Consensus Conference in 2005 and 2014
[43,44]. For the CRPC patients (series 5), age at diag-
nosis (median 77.3 years) was recorded.
Follow-up
September 2016 was the last date of follow-up for series
1. The median follow-up time was 147.5 months for all
patients and 151.5 months for surviving patients. Time
from surgery until the following end points was
recorded: biochemical recurrence (169/338 patients),
clinical recurrence (101/338 patients), locoregional recur-
rence (77/338 patients), skeletal metastases (41/338
patients), and death (112/338 patients), including cancer-
specific death (38/338 patients) (see supplementary mate-
rial, Table S1). Two patients were lost to follow-up. An
elevated s-PSA level in two consecutive blood samples
was defined as biochemical recurrence. As a result of
more sensitive s-PSA measurements, the elevated s-PSA
level was set at ≥0.5 ng/ml if the blood sample was taken
before 31 December 1994 and ≥0.2 ng/ml after 1 January
1995. A tumour in the prostatic fossa was defined as
locoregional recurrence, as was a >50% reduction of
s-PSA or a s-PSA level <0.1 ng/ml after local radiation
therapy. Magnetic resonance imaging, X-ray, or bone
scan identified skeletal metastases.
For series 5, disease progression during androgen
ablation therapy defined castration resistance. Addi-
tional treatment with anti-androgens (bicalutamide) was
given to 8 of 33 patients prior to palliative transurethral
resection. Of 33 patients, 25 developed metastases of
the bone, lung, liver, or testis. The median time from
castration resistance to death was 28.5 months. All
patients had died by the last follow-up (2018).
Tissue microarrays
Tissue microarray (TMA) blocks (series 1–3 and 5) were
made by collecting three tissue cores (diameter
0.6–1.0 mm) from the area of the highest tumour grade per
case and moving them to a new paraffin block. Regular
sections were used for the skeletal metastases (series 4).
Immunohistochemistry
5-μm sections from formalin-fixed, paraffin-embedded
(FFPE) tissue were stained by immunohistochemistry
for Twist (rabbit polyclonal antibody [H-81]: sc-15393
[Santa Cruz Biotechnology, Santa Cruz, CA, USA]),
Slug (monoclonal rabbit antibody [C19G7] [Cell Sig-
naling Technology®, Danvers, MA, USA]), and Snail
(polyclonal rabbit antibody [H-130]: sc-28199 [Santa
Cruz Biotechnology]). Staining for Hif-1α (monoclo-
nal mouse antibody clone H1α67 [sc-53546; Santa
Cruz Biotechnology]) was performed according to pre-
vious protocols [40]. Further information regarding the
immunohistochemical staining methods can be found
in supplementary material, Table S2. Positive controls
(multiorgan TMA sections with known expression of
the relevant antigen) and negative controls (isotypic
immunoglobulin or antibody diluent without the pri-
mary antibody) were included. In addition, smooth
muscle cells in the intervening stroma served as the
positive control for Slug.
Evaluation of staining in prostate tissues
All slides were examined by one pathologist (AB).
Parts of series 1 (n = 104) and series 2–5 were exam-
ined by two pathologists (AB and KG). The evaluation
was performed with pathologists blinded to patient
information or earlier registration. To record the
staining, we used a staining index (SI; values 0–9) by
multiplying the staining intensity (values 0–3) by the
proportion of positive tumour cells (0% = 0, 1–
10% = 1, 11–50% = 2, >50% = 3) across the three tis-
sue cores from each case.
Twist, Slug, Snail, and Hif-1α variably stained
nuclei and cytoplasm (Figure 1). Nuclear expression is
presented in this study for Twist and Hif-1α. For Slug,
a super SI was calculated as the sum of the nuclear
and cytoplasmic staining indices. A prominent finding
for Snail was increased expression at the tumour–
stromal border (Snail-SB). Snail-SB was defined sub-
jectively by accentuated nuclear or cytoplasmic
staining either in the margins of tumour cell islands or
as increased staining of infiltrating single tumour cells
in contrast to weaker staining in central parts of
tumour islands, i.e. in tumour cells without apparent
stromal contact (Figure 1H,I). Snail-SB was superior
to nuclear Snail in evaluation of results, and only
Snail-SB is presented in this study.
Survival patterns and frequency distribution of quar-
tile and median values of the biomarkers were exam-
ined, and robust cut-off values were preferred; Twist
(SI ≥4 versus others) and Slug (super-SI ≥8 versus
others) were dichotomised by the median. Snail-SB
was categorised as present or absent, and Hif-1α by
the upper quartile (SI ≥6 versus others).
Intra-observer variability was tested by one patholo-
gist (AB) on 25 randomly selected cases (series 1) with
very good intra-observer agreement for Twist, Slug,
Snail-SB, and Hif-1α (kappa values ≥0.82). Series 2–5
and a subset of series 1 (n = 104) were scored by two
pathologists (AB and KG). Inter-observer agreement
was moderate to very good for Twist (kappa values
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0.45–0.94) and good to perfect for Slug, Snail-SB, and
Hif-1α (kappa values 0.71–1.0).
Evaluation of TILs
The number of tumour-infiltrating lymphocytes (TILs)
was assessed on the haematoxylin and eosin-stained
TMA slides from series 1 and graded subjectively with
four grades (0–3) (see supplementary material, Note
S1). Associations were analysed using the
categorisation of low (0–1) versus high (2–3) TILs.
For survival analyses, subgroups with similar survival
curves were merged and categorised into intermediate
TILs versus absent or very high TILs.
Biomarkers from previous studies
Biomarkers from previous studies, including FOXC2
[41], E-cadherin, N-cadherin [41,45], β-catenin [45],
microvessel density (FVIII) [46,47], VEGF-A [40],
Figure 1. Immunohistochemical staining of Twist, Slug, Snail, and Hif-1α: strong nuclear expression of Twist in localised prostatic carcinoma
(A) and weak Twist expression in localised prostatic carcinoma (B) and in BPH (C). Strong nuclear and cytoplasmic expression of Slug in localised
carcinoma (D), weak Slug in localised carcinoma (E), weak Slug in BPH (F), and strong Slug in skeletal metastasis (G). Increased staining of Snail
at the tumour–stromal border in localised prostatic carcinoma (H) and in CRPC (I). Strong nuclear Hif-1α in localised prostatic carcinoma (J),
weak Hif-1α in localised prostatic carcinoma (K), and strong Hif-1α in castration-resistant carcinoma (L). Original magnification ×400.
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vascular proliferation (Nestin/Ki-67) [40],
glomeruloid microvascular proliferation (GMP) [48],
Ki-67 [49], and p27 [50] were included in the
analyses.
Biomarker gene expression in external cohorts
Three publicly available prostate cancer gene expres-
sion data sets were analysed for validation:
GSE16560 (n = 281, FFPE tissue from transurethral
resection of prostate) [51], GSE 10645 (n = 596,
FFPE tissue from radical prostatectomies) [52], and
The Cancer Genome Atlas Prostate Adenocarcinoma
(TCGA-PRAD) database (n = 497, tissue from radical
prostatectomies). GSE 16560 was downloaded from
Gene Expression Omnibus (GEO), www.ncbi.nlm.
nih.gov/geo, and GSE 10645 from GEO (mRNA
data) and Oncomine, www.oncomine.org (clinical
data). The TCGA-PRAD database was downloaded
from cBioPortal for cancer genomics, www.
cbioportal.org. If available, databases containing
information on cancer-specific survival after radical
prostatectomy were preferred. The patients were
dichotomised by high and low expression of TWIST1,
HIF-1α, and SNAI1 using median as the cut-off for
the GSE databases and z-score > 2.0 for the TCGA-
PRAD database. Cancer-specific death was used as
the end point for GSE 16560 and GSE 10645, and
disease-free survival was used for the TCGA-PRAD
database.
Statistics
Statistical analyses were performed using the SPSS
statistical package (IBM Corp., Armonk, NY,
USA), versions 24.0–26.0. The clinicopathological
variables were dichotomised by clinically meaning-
ful cut-off points or by merging groups with com-
parable outcomes on survival analyses. Pearson’s
chi-square or Fisher’s exact test was performed for
associations between categorical variables, and the
Mann–Whitney U or Kruskal–Wallis test was used
for continuous variables. The McNemar test and
Wilcoxon signed rank test were used to compare
related samples. Cohen’s kappa statistics was used
to evaluate inter- and intra-observer agreement.
The product-limit method (log-rank test) was used
for univariate survival analyses, and Kaplan–Meier
plots were computed. The Cox proportional haz-
ards method and the likelihood ratio test were per-
formed for multivariate analysis, including
variables with p < 0.10 in univariate analysis.
Log–log plots were used to examine model
assumptions of proportionality, and possible inter-
actions were tested.
Results
Individual expression of EMT regulators associate
with adverse clinicopathological features and
predict survival
Twist expression was recorded as strong in 161 of
334 (48%), Slug in 157 of 332 (47%), Snail-SB in
115 of 333 (35%), and Hif-1α in 80 of 334 (24%) of
the prostatectomy cases.
Strong expression of Twist, Slug, and Snail-SB was
associated with high Gleason score (≥GG3 [4 + 3] ver-
sus ≤GG2 [3 + 4]) (Figure 2A), but only Snail-SB was
associated with Gleason GG5 (p < 0.0005)
(Figure 2B). Among 15 cases with heterogenous
Gleason patterns, Twist or Slug did not differ between
different Gleason patterns, whereas all cases with
increased Snail-SB (9/15) were found in the higher and
not in the lower Gleason patterns (p = 0.004). Further-
more, strong Slug and Snail-SB were associated with
nearly all other unfavourable clinicopathological vari-
ables, and Hif-1α was associated with none (Table 1).
Strong Slug was associated with strong FOXC2, strong
β-catenin, and high Ki-67, and Snail-SB was associated
with strong FOXC2, low E-cadherin, EN-switch, weak
β-catenin, weak p27, and increased s-PSA (Mann–Whit-
ney, p = 0.001). In addition, the biomarkers were associ-
ated with each other (see supplementary material,
Table S3): strong Twist with strong Slug expression
(p < 0.0005), strong Twist and Slug with strong Hif-1α
(p = 0.001 and p < 0.0005), and strong Slug with
Snail-SB (p = 0.014).
In univariate survival analyses, strong Twist, Slug,
and Snail-SB were associated with shorter time to bio-
chemical, clinical, and locoregional recurrence and
cancer-specific death (Figure 3 and supplementary
material, Table S4). Strong Hif-1α was associated with
clinical recurrence (Figure 3 and supplementary mate-
rial, Table S4). Evaluation of these biomarkers within
the subgroup of Gleason score 7 carcinomas broadly
gave a trend for similar, although less significant,
results compared with using the complete series (data
not shown).
In multivariate models, Twist, Slug, Snail-SB, and
Hif-1α were introduced individually together with the
three standard prognostic variables: Gleason score
(≥GG3 [4 + 3] versus ≤GG2 [3 + 4]), pathological
stage (≥pT3 versus pT2), and preoperative s-PSA
(>13.3 versus ≤13.3, upper quartile). Survival data for
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Figure 2. Strong expression of Twist, Slug, Snail-SB, and Hif-1α (%) in Gleason grade group ≥GG3 (4 + 3) versus ≤GG2 (3 + 4) (A) and
in Gleason Grade Groups 1–5 (B) in localised prostatic carcinomas. Mean Twist SI (C), mean Slug super SI (D), Snail at tumour–stromal
border (%) (E), mean Hif-1α SI (F), and co-expression (%) of Snail-SB and E-cadherin (G) in different prostatic tissues (95% CI).
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univariate clinicopathological variables are previously
described [41]. Twist and Slug tended to be indepen-
dent predictors of biochemical (hazard ratio [HR] 1.6,
p = 0.005; HR 1.3, p = 0.087) and locoregional recur-
rence (HR 1.6, p = 0.060; HR 1.6, p = 0.041). Hif-1α
tended to be an independent predictor of biochemical,
clinical, and locoregional recurrence (HR 1.4–1.7,
p ≤ 0.054). Gleason score and pathological stage
remained independent predictors in the models
(Table 2). Snail-SB was not an independent predictor
of any end point.
The link between EMT regulators, adverse features,
and outcome is strongly sustained in carcinomas
with E-cadherinlow phenotype
E-cadherin staining was weak in 76 of 335 (23%) of
the cases in series 1, indicating ongoing EMT [41]. In
Figure 3. Univariate survival analyses (Kaplan–Meier) according to expression of Twist (A–D), Slug (E-H), Snail-SB (I-L), and Hif-1α
(M–P) in patients with clinically localised prostatic adenocarcinoma (338 radical prostatectomies). End points: biochemical recurrence,
clinical recurrence, locoregional recurrence, and cancer-specific death.
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this subgroup, strong Twist was associated with high
Gleason score (p = 0.028) and lymph node infiltration
(p = 0.034), whereas strong Slug and Snail-SB were
associated with high Gleason score, extra-prostatic
extension, seminal vesicle invasion, high pathological
stage, and positive surgical margins (p ≤ 0.048) (see
supplementary material, Table S5). In univariate sur-
vival analyses, Slug was associated with all end points,
and Twist, Snail-SB, and Hif-1α were associated with
most end points (Figure 4, and supplementary mate-
rial, Figure S1 and Table S6). Multivariate models
showed that Slug was an independent predictor of clin-
ical and locoregional recurrence, skeletal metastases,
and cancer-specific death (HR 2.3–3.3, p ≤ 0.04)
(Table 3), and Hif-1α was an independent predictor of
clinical and locoregional recurrence (HR 3.9–4.9,
p ≤ 0.008) together with Gleason score.
The above results support a convincing relation
between EMT regulators and aggressive tumour
features and outcome in prostate cancer.
Co-expression of factors strengthens relations to
adverse features and outcome
Co-expression of Twist–Slug and Twist–Slug–Snail-
SB revealed an even more striking association with
unfavourable clinicopathological features and poor
outcome (see supplementary material, Note S2,
Tables S7 and S8, and Figure S2). Furthermore, the
patients were classified into two groups based on
expression of Twist, Slug, Snail-SB, and Hif-1α:
zero to two strong biomarkers (263/331, 79%) versus
three to four strong biomarkers (68/331, 21%).
Co-expression of three to four biomarkers was associ-
ated strongly with all unfavourable clinicopathological
features (Table 1) and all end points (Figure 4 and
supplementary material, Table S8). In multivariate
survival analysis, co-expression of three to four bio-
markers independently predicted biochemical, clinical,
and locoregional recurrence (HR 1.6–2.5, P = 0.014 to
<0.0005) consistently together with Gleason score and
pathological stage (Table 2).
Figure 4. Univariate survival analyses (Kaplan–Meier) according to expression of Slug (A–E) in patients with E-cadherinlow, clinically
localised prostatic adenocarcinoma (76 radical prostatectomies), according to number of co-expressing factors (Twist, Slug, Snail-SB,
and Hif-1α; 3–4 strong versus 0–2 strong) (F–J) in patients with clinically localised prostatic adenocarcinoma (338 radical prostatecto-
mies) (end points: biochemical recurrence, clinical recurrence, locoregional recurrence, skeletal metastases, and cancer-specific death)
and according to mRNA expression of TWIST1 in 281 prostate cancer patients with cancer-specific death as end point (K); mRNA expres-
sion of HIF-1α in 596 prostate cancer patients with cancer-specific death as end point (L), mRNA expression of SNAI1 in 497 prostate
cancer patients with disease-free survival as end point (M), and co-expression of Snail-SB and E-cadherin in patients with castration-
resistant prostatic carcinoma with time from castration resistance to death as end point (N).
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EMT regulators are associated with angiogenesis
As summarised in Table 1, both individual expression
and co-expression of the biomarkers were associated
with vascular factors. Strong Twist was associated
with high vascular proliferation (Nestin/Ki-67); strong
Slug with maximum microvessel density (FVIII); and
Snail-SB with presence of GMP, strong VEGF-A, and
increased Nestin/Ki-67. Hif-1α above the lower tertile
and co-expression of three to four biomarkers were
associated with the presence of GMP. Among E-cad-
herinlow carcinomas, strong Twist (p = 0.018) and Slug
(p = 0.073, borderline) were associated with Nestin/
Ki67, and strong Slug was associated with microvessel
density (p = 0.026) (see supplementary material,
Table S5). Taken together, the above data support a
link between EMT and angiogenesis.
EMT regulators are associated with high numbers
of TILs
Strong expression of Twist, Slug, and Hif-1α and
co-expression of Twist, Slug, Snail-SB, and Hif-1α
were associated with high TILs (p ≤ 0.044) as seen in
supplementary material, Table S9. Absence of TILs or
very high TILs was associated with shorter time to
most end points compared to the subgroup with an
intermediate number of TILs (see Supplementary
material, Figure S3).
Survival analyses by gene expression
In univariate survival analyses, high TWIST1 (GSE
16560) and HIF-1α (GSE 10645) mRNA were associ-
ated with reduced cancer-specific survival, and high
SNAI1 (TCGA-PRAD database) mRNA was associ-
ated with reduced disease-free survival (p = 0.001,
p = 0.005, and p = 0.015) (Figure 4K–M). In multivar-
iate survival analyses, high TWIST1 (GSE 16560)
tended to be an independent predictor of cancer-
specific death (HR 1.3, 95% confidence interval [CI]
1.0–1.7, p = 0.053) together with Gleason score (HR
3.6, 95% CI 2.7–4.7, p < 0.0005). HIF-1α (GSE
10645) was not an independent predictor of cancer-
specific death (HR 1.4, 95% CI 0.9–2.3, p = 0.167)
when including preoperative s-PSA, Gleason score,
and pathological stage in the model. SNAI1 (TCGA-
PRAD database) was an independent predictor of dis-
ease recurrence with borderline significance (HR 1.8,
95% CI 1.0–3.5, p = 0.088) together with Gleason
score and pathological stage. No survival differences
were found for SNAI2 (GSE 16560 and TCGA-PRAD
database).
Biomarker expression in different prostatic tissues
Expression of the biomarkers was analysed in tissues
from BPHs, localised carcinomas, lymph node metasta-
ses, distant soft tissue metastases, skeletal metastases, and
castration-resistant carcinomas, as seen in Figure 2C–G.
Twist expression was strong in the localised carcinomas
but strikingly reduced in the distant metastases. Slug, on
the other hand, was strongest in the skeletal metastases.
Snail-SB was most frequently seen in the distant metasta-
ses and in the CRPCs.
Hif-1α expression has been evaluated previously
[40]. After re-evaluation of the material, partition of
series 3 into lymph node and distant soft tissue metas-
tases, new patient follow-up, and expansion of series
1, Hif-1α expression was still strongest in CRPCs,
skeletal metastases, and distant soft tissue metastases.
Table 3. Multivariate survival analysis (Cox proportional hazards
method) according to expression of Slug in patients with E-
cadherinlow, clinically localised prostatic adenocarcinoma
(76 radical prostatectomies). End points: clinical recurrence,
locoregional recurrence, skeletal metastasis, and cancer-specific
death.
Variables No. HR 95% CI P value*
Clinical recurrence
Gleason score†
≤3 + 4 38 1.0
≥4 + 3 37 2.2 1.0–5.0 0.055
Slug‡
Low 45 1.0
High 30 2.3 1.0–5.1 0.034
Locoregional recurrence
Gleason score†
≤3 + 4 38 1.0
≥4 + 3 37 2.4 0.9–6.4 0.069
Slug‡
Low 45 1.0
High 30 2.5 1.0–6.2 0.042
Skeletal metastases
Gleason score†
≤3 + 4 38 1.0
≥4 + 3 37 3.9 1.1–14.0 0.021
Slug‡
Low 45 1.0
High 30 3.3 1.0–10.4 0.031
Cancer-specific survival
Gleason score†
≤3 + 4 38 1.0
≥4 + 3 37 5.9 1.3–26.4 0.005
Slug‡
Low 45 1.0
High 30 3.0 1.0–9.5 0.041
*Likelihood ratio test.
†Gleason score in radical prostatectomy specimens.
‡Cytoplasmic and nuclear expression, cut-off by median.
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Snail-SB/E-cadherin co-expression was not found in
BPHs. However, it was most frequent among the dis-
tant soft tissue metastases and skeletal metastases
(Figure 2G).
Biomarker expression in matched samples
Five patients from series 1 had matching pelvic lymph
node metastases in series 3. Strong Twist and Slug
were observed in none and one of the five lymph node
metastases, respectively, but were found in four of five
and all five of the localised carcinomas (p = 0.066 and
p = 0.043 [SI]). Significant differences were not found
for Snail-SB or Hif-1α.
Biomarker expression in CRPC
In the CRPCs, Snail-SB was associated with positive
N-cadherin (p = 0.036) and strong Slug (SI ≥ 8, upper
quartile) (p = 0.050). Positive Twist (SI ≥ 1, median)
was associated with strong Hif-1α (SI ≥ 6, median)
(p = 0.044), and Snail-SB/E-cadherin co-expression
was associated with positive N-cadherin (p = 0.018).
Strong Twist (SI ≥ 3, >upper quartile) was associ-
ated with shorter time from castration resistance to
death (p = 0.003). Strong Hif-1α (SI ≥ 6, median, new
follow-up) and Snail-SB/E-cadherin co-expression
were borderline associated with reduced survival in
these patients (p = 0.084 and p = 0.056) (Figure 4N
and see supplementary material, Figure S4). In multi-
variate survival analysis, including Twist, Hif-1α,
E-N-cadherin co-expression, Nestin/Ki67, and Snail-
SB/E-cadherin, strong Twist and Snail-SB/E-cadherin
were independent predictors of time from castration
resistance to death (HR 9.2, 95% CI 2.2–38.7,
p = 0.009; HR 2.5, 95% CI 1.1–5.9, p = 0.045).
Strong Nestin/Ki67 was of borderline significance (HR
2.0, 95% CI 0.9–4.6, p = 0.093).
Discussion
In prostate cancer, transcription factors regulating
EMT and angiogenesis have not been well studied,
nor has their interplay. Here, we demonstrated a strong
link between the EMT regulators Twist, Slug, and
Snail and aggressive tumour features and disease pro-
gression with long follow-up in prostate cancer, with
novel relations to hypoxia and angiogenesis, including
a stronger impact by co-expression of the biomarkers.
Twist, one of the key EMT regulators central to
carcinoma progression [6], was over-expressed in our
localised prostatic carcinomas compared to BPH, and
strong expression was associated with adverse factors
and poor outcome. However, the EMT programme is
plastic [3], and Twist activation may represent a tran-
sient phenomenon, with Twist downregulation
favouring tumour initiation at the metastatic site [53].
In line with this, Twist was markedly reduced in the
distant metastases in our material. Tumour cells with a
hybrid epithelial–mesenchymal phenotype have been
linked to stemness, aggressiveness, and drug resistance
[54]. As these cancer cells have both adhesive and
migratory abilities, they may move as clusters in the
blood stream and more efficiently lead to metastases
[55], and such plasticity is associated with poor patient
outcome [56]. Corresponding with the above, a colon
cancer cell line study demonstrated expression of both
epithelial markers and Snail in circulating tumour
cells [57]. Corroborating these studies, we found
co-expression of Snail-SB and E-cadherin in approxi-
mately 50% of the distant metastases. Among our
CRPC patients, this hybrid epithelial–mesenchymal
phenotype was borderline associated with reduced
survival and was an independent predictor of time to
death. However, epithelial plasticity makes the
targeting of EMT-inducing factors used as mon-
otherapy complicated as reversal of EMT might lead
to the establishment of macro-metastases in patients
with disseminating disease or circulating tumour cells
at the time of treatment [58]. Thus, a strategy for clini-
cal application of EMT-based therapy may be to target
the hybrid epithelial–mesenchymal phenotype [59].
The subgroup of carcinomas expressing low E-
cadherin [41] in our material may represent tumours
with ongoing EMT. As in localised carcinomas, Slug
had an even more striking and strong relation to multi-
ple adverse factors, disease progression, and cancer-
specific death in this subgroup, probably reflecting the
additional roles of the EMT inducer Slug, such as its
effect on cell proliferation and pro-survival activ-
ity [18]. Likewise, in a study of colorectal carcinomas,
tumours with both strong Slug and weak E-cadherin
expression showed the worst prognosis [28].
Our finding of increased Snail expression at the
tumour–stroma interface, possibly linked to the EN-
switch, support that Snail, under certain conditions
and tumour types, could be involved in the initial
stages of invasion and be an early marker of EMT in
contrast to Twist and Slug, which could be responsible
for the maintenance of the migratory, malignant nature
of the tumour cells [18]. While Slug and Snail repress
E-cadherin expression directly by binding to the
E-boxes of the E-cadherin promoter, Twist appears
to depend on Slug activation to promote EMT by
inducing Slug at the promoter level [60].
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Expression of EMT biomarkers differed between
our skeletal metastases and lymph node metastases
and between the matched samples of localised carcino-
mas and lymph node metastases. The weaker expres-
sion of Slug and Snail in the lymph node metastases
supports the theory that EMT might not be required
for lymph node colonisation as collective sheet migra-
tion of cancer cells has been shown to have the ability
to colonise lymphatics [53,61].
In prostate cancer cells, Hif-1α induces an EMT
phenotype [62], and it has been demonstrated that
Hif-1α directly binds to the hypoxia response element
in the promoter region of Twist to increase transcrip-
tion [5,63]. Hif-1α can also regulate the expression
of Slug and Snail and lead to increased cancer
stemness during tumour progression, thus mechanisti-
cally linking hypoxia to the EMT programme and
increasing the metastatic potential [64]. In our study,
strong Twist and Slug expression associated with
strong Hif-1α in localised carcinomas and the relation
between Twist and Hif-1α was sustained in CRPC,
indicating an important association between hypoxia
and EMT both before and after androgen deprivation
therapy. It appears that our present study is the first to
report this relationship in clinical tumour specimens
from prostate cancer patients.
Associations were also found between strong Twist
expression and strong Slug and between strong Slug
and Snail-SB in our localised prostatic carcinomas.
Co-expression of the EMT biomarkers was associated
with aggressive tumour features and demonstrated
an enhanced effect on outcome as suggested for other
tumour types [8,9]. Furthermore, patients with
co-expression of more than any two of Twist, Slug,
Snail-SB, or Hif-1α demonstrated poorer outcome.
Our data are in line with the experience that EMT reg-
ulators may act collectively and have an impact on
each other [7], also in prostate cancer, and support a
connection between EMT and hypoxia.
Hif-1α is a key regulator of angiogenesis [65,66].
Angiogenic factors, such as VEGF-A, have been
shown to be upregulated in cancer cells during EMT
and in cancer stem cells [67], and Twist, Slug, and
Snail have been linked to angiogenesis via VEGF
[21,22,24]. In addition to associations found between
the EMT biomarkers and Hif-1α, strong expression of
all three EMT-biomarkers was related to VEGF,
microvessel density, microvascular proliferation, or
GMP. Our data suggest a close relationship between
EMT and angiogenesis in prostate cancer, possibly
co-regulated and driven by Hif-1α.
By using a large retrospective cohort, we have
achieved long and complete follow-up of the patients
with several end points, including cancer-specific
death. During 1986–2007, changes were made to the
diagnosis and management of prostate cancer, espe-
cially by the introduction of s-PSA in the 1990s,
and we are aware of the diversity of these patients.
Furthermore, newer medications, such as abiraterone
and enzalutamide, have been introduced after the
patients in our series were treated. An effect of these
newer medications cannot be assessed in our retrospec-
tive cohort of CRPCs. Validation of the results in
independent, more up-to-date cohorts would be valuable.
Direct pharmacological inhibition of EMT transcription
factors is difficult [68]. Alternative approaches to target
EMT are described using metabolic inhibitors [69] or
nanomaterials [70]. Examples include suramin for prostate
cancer [71], inhibition of inducible nitric oxide synthase
for triple negative breast cancer [72], and chitosan as a
nanocarrier for SN38 and Snail-specific siRNA in prostate
cancer cells [73]. These approaches have been shown to
downregulate Twist [72], Slug [72,74], and Snail [72,73].
Furthermore, the crosstalk between tumour cells undergo-
ing EMT and immune cells in the tumour microenviron-
ment has garnered increasing interest and may provide
possibilities for combining immunotherapy with EMT-
targeted therapy or for using EMT score as a potential
predictive marker for immunotherapy response [75,76]. In
our study, we have investigated the relationship between
EMT and tumour-associated chronic inflammation. In
contrast to most other solid malignancies, a high number
of TILs is often associated with poor patient outcome in
prostate cancer [77]. Immune evasion in this situation can
possibly be explained by the relative distribution of
T-regulatory and effector cells [78]. Paralleling our find-
ings that the absence of TILs is also linked to poor out-
come, very low and very high numbers of CD3+ T cells
were associated with shorter time to biochemical recur-
rence compared to patients with intermediate numbers of
CD3+ T cells in prostate cancer [79]. Our findings of the
significant associations between strong expression of
Twist, Slug, and Hif-1α and high TILs may also be rele-
vant for the future management of prostate cancer and
invite further investigation. The potential for translational
applicability of EMT may be improved by more knowl-
edge about the plasticity of the EMT programme; its com-
plex, dynamic, and interrelated regulation; and connection
to cells in the tumour microenvironment. Treatment
directed against epithelial–mesenchymal plasticity and
related processes such as angiogenesis and hypoxia might
be provided simultaneously and be tailored according to
the expression of their respective transcriptional regulators
and markers in different stages of the disease.
To summarise, our study provides new findings
regarding the prognostic value of EMT in prostate
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cancer using several end points, with increased prog-
nostic influence by co-expression of EMT biomarkers.
We identify a subgroup of patients with low expression
of E-cadherin and strong expression of Slug with espe-
cially poor outcome; this may be a subgroup that may
particularly benefit from future targeted therapy. We
demonstrate an important, novel link between EMT and
hypoxia, as well as angiogenesis in prostate cancer, and
we find decreased Twist at the metastatic site, possibly
indicating epithelial–mesenchymal plasticity. Taken
together, our findings may contribute to prognostication
and selection of prostate cancer patients for potential
combined tailored treatment in the future.
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